^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
04/26/2021
Excerpt:
Vulvar cancer (Squamous cell carcinoma): Advanced or recurrent/metastatic disease…Biomarker-directed systemic therapy for second-line treatment…Larotectinib or entrectinib for NTRK gene fusion-positive tumors...
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Solid Tumor)
New
Excerpt:
ROZLYTREK is a kinase inhibitor indicated for the treatment of...Adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation.